News | October 23, 2024
Sumitomo Corporation entered into contract with Revorf
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Subscribe To Our Newsletter & Stay Updated
